Table 1.
Clinical and demographic characteristics of the study cohort.
Fig 1.
BBIBP-CorV: Sinopharm vaccine; ChAdOx1 nCoV-19: AstraZeneca; COVID-19 vaccine: Coronavirus disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.
Fig 2.
Seropositivity rates and IgM antibody levels in response to SARS-CoV-2 as a function of time since symptom onset.
(A) The graph shows the number of participants tested positive (dark blue) and negative (light blue) for IgM antibodies, as well as the rate of seropositivity (red curve) as a function of the number of days after symptom onset at follow-up. (B) Box plots s display the distribution and differences in anti-SARS-CoV-2 IgM antibody levels for participants sampled at different follow-up periods. P-values were calculated using the Mann-Whitney test.
Fig 3.
The differences in IgM antibody levels between different groups.
(A) The first graph compares IgM antibody levels between genders (F for female and M for male), showing the distribution of antibody levels in each group. (B) IgM antibody levels are shown as a function of age, with the 190 participants divided into two groups: under 50 years and over 50 years. Each age interval is represented by a separate box plot. (C) IgM antibody levels according to the presence or absence of comorbidities. The box plots show the distribution of antibody levels in each group. In all three graphs, the P-values are calculated using the Mann-Whitney test.
Fig 4.
Seropositivity rates and IgA antibody levels in response to SARS-CoV-2 as a function of time since symptom onset.
(A) Graph shows the number of participants tested positive (dark blue) and negative (light blue) for IgA antibodies, as well as the rate of seropositivity (red curve) as a function of the number of days after symptom onset at follow-up. (B) Box plots show the distribution and differences anti-SARS-CoV-2 IgA antibody levels for participants sampled at different follow-up periods. P-values were calculated using the Mann-Whitney test.
Fig 5.
Differences in IgA antibody levels between different groups.
(A) The first graph compares the IgA antibody levels between the sexes (F for female and M for male), showing the distribution of antibody levels in each group. (B) IgA antibody levels are shown as a function of age, with the 190 participants divided into two groups: under 50 years and over 50 years. Each age interval is represented by a separate box plot. (C) Displays IgA antibody levels according to the presence or absence of comorbidities. The box plots show the distribution of antibody levels in each group. In all three graphs, P-values are calculated using the Mann-Whitney test.
Fig 6.
Seropositivity rate and anti-RBD IgG antibody level in response to SARS-CoV-2 as a function of time since symptom onset.
(A) The number of participants ested positive (dark blue) and negative (light blue) for anti-RBD IgG antibodies, as well as the seropositivity rate (red curve) as a function of days after symptom onset at follow-up. (B) Distribution and difference in levels of anti-SARS-CoV-2 anti-RBD IgG antibody levels for participants sampled at different follow-up periods. Each box plot represents a different follow-up period, and P-values are calculated using the Mann-Whitney test.
Fig 7.
Distribution and differences of anti-RBD IgG antibodies to SARS-CoV-2 by sex, age, and comorbidity during follow-up.
(A) anti-RBD IgG antibody levels by sex, with the distribution of antibody levels in each group represented by box plots. (B) anti-RBD IgG antibody levels by age, with the 167 participants divided into two groups based on age: under 50 years and over 50 years. Each age range is represented by a separate box plot. (C) IgG antibody levels according to the presence or absence of comorbidities, with the distribution of antibody levels in each group represented by box plots. In all three graphs, P-values are calculated using the Mann-Whitney test.
Fig 8.
Seropositivity rate and anti-N IgG antibody levels in response to SARS-CoV-2 as a function of time since symptom onset.
(A) The number of participants tested positive (dark blue) and negative (light blue) for anti-N IgG antibodies, as well as the seropositivity rate (red curve) as a function of the number of days after symptom onset at follow-up. (B) Distribution and difference in levels of of anti-SARS-CoV-2 anti-N IgG antibody levels for participants sampled at different follow-up periods. Each box plot represents a different follow-up period, and P-values are calculated using the Mann-Whitney test.
Fig 9.
Distributions and differences of anti-N IgG antibodies to SARS-CoV-2 by sex, age, and comorbidity at follow-up.
(A) anti-N IgG antibody levels by sex, with the distribution of antibody levels in each group represented by box plots. (B) anti-N IgG antibody levels by age, with the 190 participants divided into two groups based on age: under 50 years and over 50 years. Each age range is represented by a separate box plot. (C) anti-N IgG antibody levels according to the presence or absence of comorbidities, with the distribution of antibody levels in each group represented by boxplots. In all three graphs, P-values are calculated using the Mann-Whitney test.
Fig 10.
Comparison of IgM antibody levels between two groups of patients according to time since onset of symptoms.
Unvaccinated infected patients (red box) and vaccinated patients before infection (green box). P-values are calculated by the Mann-Whitney test.